## Anti-ATG13 [ATG13]

Catalogue number: 151612 Sub-type: Primary antibody

Images:

#### Contributor

**Inventor:** Sharon Tooze

Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Images:

### **Tool details**

# ZancerTools.org \*FOR RESEARCH USE ONLY

Name: Anti-ATG13 [ATG13]

Alternate name:

Class: Polyclonal

Conjugate: Unconjugated

**Description:** Atg13 only binds in the unphosphorylated state, and its dephosphorylation has been

shown to be TOR dependent.

Purpose: Parental cell: Organism: Tissue: Model: Gender: Isotype:

Reactivity: Human

Selectivity: Host: Rabbit

Immunogen: C-terminal synthetic peptide

**Immunogen UNIPROT ID:** 

Sequence:

**Growth properties: Production details:** 

Formulation:

**Recommended controls: Bacterial resistance:** Selectable markers:

#### Additional notes:

## **Target details**

Target: ATG13

#### **Target alternate names:**

**Target background:** Autophagy has been implicated in a number of medical contexts, such as cancer, neurodegeneration, and immunity. The serine-threonine protein kinase Atg1 was originally identified as a critical autophagy regulator in yeast. Full kinase activity of Atg1 in yeast requires its binding partners Atg13 and Atg17.

Cancer Tools.org

#### Molecular weight:

Ic50:

## **Applications**

**Application:** WB **Application notes:** 

## **Handling**

Format: Liquid
Concentration:
Passage number:
Growth medium:
Temperature:
Atmosphere:
Volume:

Storage medium: Storage buffer: Storage conditions:

Shipping conditions: Shipping at 4° C

#### Related tools

Related tools:

## References

References: Foxler et al. 2018. EMBO Mol Med. 10(8):. PMID: 29930174. ; A HIF-LIMD1 negative

feedback mechanism mitigates the pro-tumorigenic effects of hypoxia.

